The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Methamphetamine-Related Psychiatric Symptoms and Reduced Brain Dopamine Transporters Studied With PET
Abstract
OBJECTIVE: A positron emission tomography (PET) study has suggested that dopamine transporter density of the caudate/putamen is reduced in methamphetamine users. The authors measured nucleus accumbens and prefrontal cortex density, in addition to caudate/putamen density, in methamphetamine users and assessed the relation of these measures to the subjects' clinical characteristics. METHOD: PET and 2-beta-carbomethoxy-3beta-(4-[(11)C] fluorophenyl)tropane, a dopamine transporter ligand, were used to measure dopamine transporter density in 11 male methamphetamine users and nine male comparison subjects who did not use methamphetamine. Psychiatric symptoms in methamphetamine users were evaluated by using the Brief Psychiatric Rating Scale and applying a craving score. RESULTS: The dopamine transporter density in all three of the regions observed was significantly lower in the methamphetamine users than the comparison subjects. The severity of psychiatric symptoms was significantly correlated with the duration of methamphetamine use. The dopamine transporter reduction in the caudate/putamen and nucleus accumbens was significantly associated with the duration of methamphetamine use and closely related to the severity of persistent psychiatric symptoms. CONCLUSIONS: These findings suggest that longer use of methamphetamine may cause more severe psychiatric symptoms and greater reduction of dopamine transporter density in the brain. They also show that the dopamine transporter reduction may be long-lasting, even if methamphetamine use ceases. Further, persistent psychiatric symptoms in methamphetamine users, including psychotic symptoms, may be attributable to the reduction of dopamine transporter density.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996) · Nature · doi:10.1038/379606a0 · Cited by 2,476
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
The behavioural and motor consequences of focal lesions of the basal ganglia in man
Bhatia, K. P., & Marsden, C. D. (1994) · Brain · doi:10.1093/brain/117.4.859 · Cited by 1,073
Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
Wilson, J. M., Kalasinsky, K. S., Levey, A. I., Bergeron, C., Reiber, G., Anthony, R. M., Schmunk, G. A., Shannak, K., Haycock, J. W., & Kish, S. J. (1996) · Nature Medicine · doi:10.1038/nm0696-699 · Cited by 718
Andreasen, N. C., O'Leary, D. S., Cizadlo, T., Arndt, S., Rezai, K., Ponto, L. L., Watkins, G. L., & Hichwa, R. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9985 · Cited by 625
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602
Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.
Hastings, T. G., Lewis, D. A., & Zigmond, M. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1956 · Cited by 547
Effects of chronic cocaine abuse on postsynaptic dopamine receptors
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.6.719 · Cited by 421
Localization of drug reward mechanisms by intracranial injections
Wise, R. A., & Hoffman, D. C. (1992) · Synapse · doi:10.1002/syn.890100307 · Cited by 275
Cited by
Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101
A review of the clinical pharmacology of methamphetamine
Cruickshank, C. C., & Dyer, K. R. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02564.x · Cited by 769
Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine
Thompson, P. M., Hayashi, K. M., Simon, S. L., Geaga, J. A., Hong, M. S., Sui, Y., Lee, J. Y., Toga, A. W., Ling, W., & London, E. D. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0713-04.2004 · Cited by 760
Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis
Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9031-0 · Cited by 671
Psychiatric Symptoms in Methamphetamine Users
Zweben, J. E., Cohen, J. B., Christian, D., Galloway, G. P., Salinardi, M., Parent, D., Iguchi, M., & Methamphetamine Treatment Project (2004) · The American Journal on Addictions · doi:10.1080/10550490490436055 · Cited by 468
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons
RIPPETH, J. D., HEATON, R. K., CAREY, C. L., MARCOTTE, T. D., MOORE, D. J., GONZALEZ, R., WOLFSON, T., GRANT, I., & GROUP, T. H. (2004) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617704101021 · Cited by 435
The need for speed: an update on methamphetamine addiction
Barr, A. M., Panenka, W. J., MacEwan, G. W., Thornton, A. E., Lang, D. J., Honer, W. G., & Lecomte, T. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0635 · Cited by 434
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432
Structural and metabolic brain changes in the striatum associated with methamphetamine abuse
Chang, L., Alicata, D., Ernst, T., & Volkow, N. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01782.x · Cited by 430
Deficits in response inhibition associated with chronic methamphetamine abuse
Monterosso, J. R., Aron, A. R., Cordova, X., Xu, J., & London, E. D. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.02.002 · Cited by 425
Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies
Volkow, N. D., Fowler, J. S., & Wang, G.-J. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00008 · Cited by 398
Implications of Chronic Methamphetamine Use: A Literature Review
Meredith, C. W., Jaffe, C., Ang-Lee, K., & Saxon, A. J. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220591003605 · Cited by 393
Methamphetamine causes microglial activation in the brains of human abusers
Sekine, Y., Ouchi, Y., Sugihara, G., Takei, N., Yoshikawa, E., Nakamura, K., Iwata, Y., Tsuchiya, K. J., Suda, S., Suzuki, K., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1179-08.2008 · Cited by 381
Self-citationNORDAHL, T. E., Salo, R. E., & Leamon, M. H. (2003) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.15.3.317 · Cited by 371
A somatic marker theory of addiction
Verdejo-García, A., & Bechara, A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.035 · Cited by 363
Brain Serotonin and Dopamine Transporter Bindings in Adults With High-Functioning Autism
Nakamura, K., Sekine, Y., Ouchi, Y., Tsujii, M., Yoshikawa, E., Futatsubashi, M., Tsuchiya, K. J., Sugihara, G., Iwata, Y., Suzuki, K., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.137 · Cited by 352
Self-citationAshok, A. H., Mizuno, Y., Volkow, N. D., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0135 · Cited by 330
LUNDQVIST, T. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.02.017 · Cited by 331
Methamphetamine and cardiovascular pathology: a review of the evidence
Kaye, S., McKetin, R., Duflou, J., & Darke, S. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01874.x · Cited by 319
Brain Serotonin Transporter Density and Aggression in Abstinent Methamphetamine Abusers
Sekine, Y., Ouchi, Y., Takei, N., Yoshikawa, E., Nakamura, K., Futatsubashi, M., Okada, H., Minabe, Y., Suzuki, K., Iwata, Y., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.1.90 · Cited by 287
Self-citationJayanthi, S., Deng, X., H. Noailles, P., Ladenheim, B., & Lud Cadet, J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0295com · Cited by 278
Neurotoxicity of substituted amphetamines: Molecular and cellular mechanisms
Cadet, J. L., Krasnova, I. N., Jayanthi, S., & Lyles, J. (2007) · Neurotoxicity Research · doi:10.1007/bf03033567 · Cited by 272
Effects of Methamphetamine Dependence and HIV Infection on Cerebral Morphology
Jernigan, T. L., Gamst, A. C., Archibald, S. L., Fennema-Notestine, C., Mindt, M. R., Marcotte, T. L., Heaton, R. K., Ellis, R. J., & Grant, I. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1461 · Cited by 268
Potential adverse effects of amphetamine treatment on brain and behavior: a review
Berman, S. M., Kuczenski, R., McCracken, J. T., & London, E. D. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.90 · Cited by 261
Epigenetic Mediation of Environmental Influences in Major Psychotic Disorders
Rutten, B. P. F., & Mill, J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp104 · Cited by 244
Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers
Johanson, C.-E., Frey, K. A., Lundahl, L. H., Keenan, P., Lockhart, N., Roll, J., Galloway, G. P., Koeppe, R. A., Kilbourn, M. R., Robbins, T., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0330-6 · Cited by 233
“Sekine and colleagues ( Sekine et al. 2001, 2003 ) also demonstrated decreases in DAT binding in the striatum and nucleus accumbens in MA users abstinent for 7 days to 1.5 years (average 6 months) compared to controls.”
BackgroundInfluentialRole of Tumor Necrosis Factor-α in Methamphetamine-Induced Drug Dependence and Neurotoxicity
Nakajima, A., Yamada, K., Nagai, T., Uchiyama, T., Miyamoto, Y., Mamiya, T., He, J., Nitta, A., Mizuno, M., Tran, M. H., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4847-03.2004 · Cited by 176
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175
“99 African American 5 (17) 6 (20) 11 (18)”
Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity
Trifilieff, P., & Martinez, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.031 · Cited by 171
Methamphetamine abuse and dentistry
Hamamoto, D., & Rhodus, N. (2009) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01459.x · Cited by 166
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers
London, E. D., Berman, S. M., Voytek, B., Simon, S. L., Mandelkern, M. A., Monterosso, J., Thompson, P. M., Brody, A. L., Geaga, J. A., Hong, M. S., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.039 · Cited by 136
Rosa-Neto, P., Lou, H. C., Cumming, P., Pryds, O., Karrebaek, H., Lunding, J., & Gjedde, A. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2004.11.031 · Cited by 135
Rose, M. E., & Grant, J. E. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802177656 · Cited by 121
Boileau, I., Rusjan, P., Houle, S., Wilkins, D., Tong, J., Selby, P., Guttman, M., Saint-Cyr, J. A., Wilson, A. A., & Kish, S. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3008-08.2008 · Cited by 100
Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood
Nemoda, Z., Szekely, A., & Sasvari-Szekely, M. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.04.002 · Cited by 78
Chou, Y.-H., Huang, W.-S., Su, T.-P., Lu, R.-B., Wan, F.-J., & Fu, Y.-K. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.05.002 · Cited by 78
“Interestingly, the psychiatric symptoms after the use of METH were correlated with DAT binding in the striatum but not the prefrontal cortex (Sekine et al., 2001).”
BackgroundResultInfluentialA placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74
An Overview of the Association between Schizotypy and Dopamine
Mohr, C., & Ettinger, U. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00184 · Cited by 63
Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1100471 · Cited by 49
Shoptaw, S., Li, M. J., Javanbakht, M., Ragsdale, A., Goodman-Meza, D., & Gorbach, P. M. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109320 · Cited by 37
Metadata
- Authors
- Sekine, Y., Iyo, M., Ouchi, Y., Matsunaga, T., Tsukada, H., Okada, H., Yoshikawa, E., Futatsubashi, M., Takei, N., & Mori, N.
- Venue
- American Journal of Psychiatry
- Published
- 2001-08-01
- Volume
- 158
- Issue
- 8
- Pages
- 1206-1214
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2014488168
- Cited by
- 406
- References
- 40
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.